## ADMA: ADMA Biologics, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.34 indicates fundamental undervaluation. Quality metrics strong (ROE 63%, ROA 22%).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($18.42)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. ADMA Biologics (ADMA): Firm Updates 2025 Revenue Guidance**
- Source: Insider Monkey | 20251221T140937 | Bullish | Relevance: 100%
- ADMA Biologics (NASDAQ:ADMA) has updated its 2025 revenue guidance to $510 million, an increase from the previous guidance of over $500 million. The company also adjusted its 2025 adjusted net income to $158 million due to a higher effective tax rate. ADMA Biologics specializes in developing and marketing plasma-derived biologics for immune deficiencies and infectious diseases.

**2. ADMA Biologics (ADMA): Firm Updates 2025 Revenue Guidance**
- Source: Finviz | 20251221T085400 | Somewhat-Bullish | Relevance: 100%
- ADMA Biologics (NASDAQ:ADMA) has updated its 2025 revenue guidance to $510 million, an increase from the previous guidance of over $500 million. The company also made a modest adjustment to its 2025 adjusted net income, now projected at $158 million, due to a higher effective tax rate. ADMA Biologics is a biopharmaceutical company focused on developing, manufacturing, and marketing plasma-derived biologics for immune deficiencies and infectious diseases.

**3. Texas Permanent School Fund Corp Has $1.87 Million Holdings in ADMA Biologics Inc $ADMA**
- Source: MarketBeat | 20251222T100931 | Bullish | Relevance: 100%
- The Texas Permanent School Fund Corp recently decreased its stake in ADMA Biologics Inc. by 39.3%, now holding 102,932 shares valued at approximately $1.87 million. Despite this, other major institutions significantly increased their positions, raising institutional ownership to 75.68%. Analysts maintain a "Buy" rating for ADMA, with a consensus price target of $28.50, following the company's meeting of EPS estimates and a 12% year-over-year revenue increase in its latest quarter.

**4. ADMA Biologics (ADMA): Firm Updates 2025 Revenue Guidance**
- Source: Yahoo Finance | 20251221T140937 | Somewhat-Bullish | Relevance: 100%
- ADMA Biologics (NASDAQ:ADMA) has updated its 2025 revenue guidance, projecting total revenue of $510 million, an increase from the previous guidance of over $500 million. The company also adjusted its 2025 adjusted net income modestly to $158 million due to a higher effective tax rate. ADMA Biologics specializes in plasma-derived biologics for immune deficiencies and infectious diseases.

**5. Perpetual Ltd Cuts Stake in ADMA Biologics Inc $ADMA**
- Source: MarketBeat | 20251220T130848 | Neutral | Relevance: 100%
- Perpetual Ltd significantly reduced its stake in ADMA Biologics Inc by 26.8% during Q3, selling 774,995 shares and retaining 2,119,291 shares valued at approximately $31.07 million. Despite Perpetual Ltd's reduction, institutional investors own about 75.68% of ADMA, and analysts maintain a "Buy" rating with a consensus price target of $28.50. ADMA Biologics recently reported Q3 EPS of $0.16 and revenue of $134.22 million, exceeding analyst expectations, with strong net margins and return on equity.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.08M) |
| Sells | 2 ($0.24M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 15.0% (-2.3%)
- Vanguard Group Inc: 8.8% (-1.8%)
- State Street Corpora: 5.7% (+12.3%)
- Invesco Ltd.: 5.2% (-2.4%)
- Sachem Head Capital : 3.8% (+100.0%)

### Key Risks

1. Elevated short interest (9.6%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.34 suggests fair value with growth premium. Forward P/E 21.1x attractive for 57% earnings growth. Quality metrics strong (ROE 63%, ROA 22%, margin 43%). Balance sheet: strong liquidity (7.1x), low leverage (D/E 0.32). Revenue growth strong at 24% YoY. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $4.7B |
| Beta | 0.43 |
| 52W Range | $13.50 - $25.67 |
| Short Interest | 9.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.34 |
| Forward P/E | 21.1 |
| Current P/E | 33.1 |
| YoY Growth | 56.7% |
| EPS Direction | RISING |

### Technicals

MRS_20 stable at 1.5% (minimal 5-day change). Below STRENGTH zone by 2.5pp (needs >4.0% for momentum thesis). MRS_5 at 1.9% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.50% (CS: 63) | Neutral |
| RSI_14 | 62.7 | Neutral |
| MACD Histogram | -0.16 | Bearish |
| vs SMA20 | 1.021x | Above |
| vs SMA50 | 1.172x | Above |
| vs SMA200 | 1.094x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $19.88
- **Stop Loss:** $18.42 (7.3% risk)
- **Target:** $22.80 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 821
- **Position Value:** $16,321.48
- **Portfolio %:** 16.32%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-03-02 (Est: $0.20)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.15 | $0.16 | +2.6% |
| 2025Q2 | $0.14 | $0.14 | +7.4% |
| 2025Q1 | $0.17 | $0.11 | -33.3% |
| 2024Q4 | $0.15 | $0.14 | -9.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*